Investors eye U.S. GDP data

Group 1: Market Overview - European stock markets are experiencing a record intraday high, with the Stoxx Europe 600 index rising as investors await US GDP data [2] - The US economy is expected to show a growth of 3.3% in Q3, driven by strong consumer spending and business investment, despite potential headwinds from inflation and government shutdown [13][15] - The healthcare sector is showing significant upside, particularly with developments in weight loss drugs, as companies like Nova Nordisk and Eli Lilly compete in this growing market [5][10] Group 2: Nova Nordisk Developments - Nova Nordisk has received FDA approval for its weight loss pill, Wiggoi, which is expected to launch early next year at a price of $149 per month [41][46] - The company aims to regain market share lost in the US, where it has faced challenges, including leadership changes and a cost-cutting program [36][46] - Analysts are optimistic about the pill's potential, noting that it offers similar efficacy to injectable options, which could attract consumers who prefer oral medications [37][50] Group 3: Competitive Landscape - The weight loss drug market is projected to reach $130 billion by 2030, with the number of patients expected to grow significantly [35] - Eli Lilly is also developing an oral weight loss drug, with expected approval around March, creating intense competition for Nova Nordisk [51][52] - The market is characterized by a flurry of mergers and acquisitions as companies vie for dominance, with Nova Nordisk previously losing a bidding war for a key drug developer [40]